Lutetium-177-DOTATATE

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

Radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT); FDA-approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Quick Facts

Property	Value
Also Known As	Lutathera, 177Lu-DOTA-[Tyr3]-octreotate, lutetium Lu 177 dotatate, 177Lu-DOTATATE
Category	Radiolabeled peptide / Peptide receptor radionuclide therapy (PRRT)
Sequence	DOTA-[Tyr3]-octreotate: D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr (cyclic, DOTA chelator at N-terminus, conjugated to 177Lu)
Molecular Weight	~1449 Da (peptide-chelator-radioisotope complex)
Molecular Formula	C65H87LuN14O19S2
PubChem CID	Not applicable (radiopharmaceutical)
Administration	IV infusion (administered at authorized nuclear medicine facilities only)
Typical Dose Range	7.4 GBq (200 mCi) per cycle; 4 cycles total
Half-Life	177Lu physical half-life: 6.647 days; effective half-life: ~50 hours (tumor-bound)
Storage	Radiopharmaceutical handling; single-use vial, administered on day of calibration
FDA Status	Approved (2018) — Lutathera for SSTR-positive GEP-NETs
WADA Status	Not listed

Mechanism of Action

Lutetium-177-DOTATATE is a targeted radiopharmaceutical that combines three components: (1) the somatostatin analog octreotate (a modified octreotide with a free carboxyl terminus providing higher SSTR2 affinity), (2) the DOTA chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) that stably binds the radioisotope, and (3) lutetium-177, a beta-emitting radionuclide with a physical half-life of 6.647 days.

The therapeutic mechanism relies on selective targeting: neuroendocrine tumor cells overexpress somatostatin receptors (particularly SSTR2). 177Lu-DOTATATE binds to SSTR2, is internalized via receptor-mediated endocytosis, and delivers cytotoxic beta radiation directly to tumor cells. The beta particles from 177Lu have a maximum energy of 0.497 MeV and a tissue penetration range of ~2 mm, enabling targeted destruction of tumor cells while sparing surrounding normal tissue. Additionally, 177Lu emits gamma photons (208 keV, 113 keV) that enable post-therapy SPECT/CT imaging for dosimetry verification.

The NETTER-1 trial (PMID 28076709) demonstrated a 79% reduction in risk of progression or death vs high-dose octreotide LAR (HR 0.21, p < 0.001). The subsequent NETTER-2 trial (PMID 38851203) extended this to first-line treatment of grade 2-3 GEP-NETs, showing a 72% risk reduction (HR 0.276, p < 0.0001).

Patient selection requires positive somatostatin receptor imaging (68Ga-DOTATATE PET/CT or OctreoScan) to confirm SSTR expression on tumor cells.

Key Research Areas

GEP-NETs (second-line) — NETTER-1 trial: HR 0.21 for PFS vs octreotide LAR in midgut NETs progressing on SSA therapy (PMID 28076709)
GEP-NETs (first-line) — NETTER-2 trial: median PFS 22.8 vs 8.5 months in grade 2-3 GEP-NETs; 72% risk reduction (PMID 38851203)
Practical implementation — Comprehensive review covering patient selection, treatment protocols, dosimetry, and long-term monitoring (PMID 35717045)
Combination strategies — Active research combining PRRT with chemotherapy (CAPTEM), immunotherapy, or molecular targeted agents

Evidence Level Summary

Evidence Type	Count	Notes
Human RCTs	2	NETTER-1 (second-line), NETTER-2 (first-line)
Narrative reviews	1	Practical clinical review
Human observational	—	ERASMUS retrospective experience, real-world data

Clinical Applications

Cancer Adjunct Therapy — FDA-approved for SSTR-positive GEP-NETs; both second-line and first-line evidence

Protocols Using This Peptide

No Ageless Peps protocols (FDA-approved radiopharmaceutical, administered only at authorized nuclear medicine facilities)

Ageless Peps Products

Not sold — Lutetium-177-DOTATATE (Lutathera) is an FDA-approved radiopharmaceutical manufactured by Novartis/Advanced Accelerator Applications. It requires specialized nuclear medicine infrastructure for preparation and administration. It is not available as a research peptide.

Dosing Reference

FDA-Approved Dosing

Indication	Route	Dose	Frequency	Duration	Source
SSTR+ GEP-NETs	IV infusion	7.4 GBq (200 mCi)	q8 weeks	4 cycles total	FDA label

Administration Requirements

Must be administered at authorized nuclear medicine facilities with radiation safety protocols
Amino acid co-infusion (lysine/arginine solution) for renal protection during and after infusion
Pre-treatment antiemetic recommended
Post-treatment radiation safety precautions for patient and caregivers

Cycling

Not applicable in the traditional sense — treatment consists of a fixed 4-cycle regimen. Retreatment may be considered in selected patients at disease progression, though data on retreatment are limited.

Contraindications & Safety

Contraindications: Pregnancy; hypersensitivity to lutetium-177-DOTATATE; severely compromised renal function (GFR <30 mL/min)
Common side effects: Nausea/vomiting (59%), fatigue (25%), lymphopenia (grade 3-4 in ~10%), thrombocytopenia (grade 3-4 in ~2%), nephrotoxicity (rare but cumulative), hepatotoxicity (in patients with high hepatic tumor burden)
Serious risks: Myelodysplastic syndrome/acute leukemia (2-5% at 5 years); bone marrow failure (rare); renal failure (rare with amino acid protection)
Drug interactions: Long-acting somatostatin analogs should be discontinued 4-6 weeks before PRRT (to avoid receptor blockade); short-acting octreotide can be used for symptom control
Pregnancy/nursing: Absolutely contraindicated; effective contraception required for 6 months after last dose (women) and 4 months (men)
Special populations: Adequate bone marrow reserve required (ANC >1500, platelets >75,000, Hgb >8); renal function monitoring mandatory; hepatic metastases are not a contraindication but require careful dosimetry

Synergistic Combinations

Octreotide — Administered concurrently (LAR 30 mg) per NETTER protocols; controls symptoms between PRRT cycles
Lanreotide — Alternative SSA for maintenance between/after PRRT cycles
Capecitabine/temozolomide — Under investigation as radiosensitizers combined with PRRT
Lutetium-177-PSMA-617 — Sister radioligand therapy; same isotope, different peptide target (PSMA vs SSTR)

Related Research

PMID	Title	Year	Study Type
28076709	NETTER-1: Phase 3 trial of 177Lu-DOTATATE for midgut NETs	2017	RCT
38851203	NETTER-2: 177Lu-DOTATATE first-line in grade 2-3 GEP-NETs	2024	RCT
35717045	Lutetium-177 DOTATATE: A Practical Review	2022	Narrative Review

References

PMID 28076709 — Strosberg et al. NETTER-1: Phase 3 trial of 177Lu-DOTATATE (2017)
PMID 38851203 — Singh et al. NETTER-2: First-line 177Lu-DOTATATE (2024)
PMID 35717045 — Mitjavila et al. 177Lu-DOTATATE practical review (2022)

FDA Disclaimer: Lutetium-177-DOTATATE (Lutathera) is an FDA-approved radiopharmaceutical. The information in this note is for educational and reference purposes only and does not constitute medical advice. Administration must be performed at authorized nuclear medicine facilities by qualified healthcare providers.

#peptide #fda-approved #not-sold #cancer-therapeutic